Related references
Note: Only part of the references are listed.Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Population Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
Nao Kawaguchi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy
Lauren Andrews et al.
BMC NEPHROLOGY (2021)
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors
Milo Gatti et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)
New Perspectives on Antimicrobial Agents: Cefiderocol
Erin K. McCreary et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics
Milo Gatti et al.
CLINICAL PHARMACOKINETICS (2021)
Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration
Andrew J. Fratoni et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update
Brian M. Hoff et al.
ANNALS OF PHARMACOTHERAPY (2020)
A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
Fekade B. Sime et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2020)
Oseltamivir and the Risk of Neuropsychiatric Events: A National, Population-Based Study
Kyungmin Huh et al.
CLINICAL INFECTIOUS DISEASES (2020)
Reply to Baud and Houze, Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?
E. Wenzler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
Matteo Bassetti et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens
Jacinda C. Abdul-Mutakabbir et al.
PHARMACOTHERAPY (2020)
A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults: The DEFINE Study
Ishaq Lat et al.
PHARMACOTHERAPY (2019)
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans
Jurgen B. Bulitta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis
Wesley D. Kufel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals
Sameer S. Kadri et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods
Stefan E. Richter et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
Rio Nakamura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review
Chandra Datta Sumi et al.
CLINICAL PHARMACOKINETICS (2019)
Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects
Carlos Sanabria et al.
CLINICAL THERAPEUTICS (2019)
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Yoshinori Yamano
CLINICAL INFECTIOUS DISEASES (2019)
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
Nao Kawaguchi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy
Soo Min Jang et al.
BLOOD PURIFICATION (2018)
Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam
Fekade B. Sime et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients
Xuemei Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae
Karlijn van Loon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
What a clinician should know about a renal replacement membrane?
Patrick M. Honore et al.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE (2018)
Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration
Claire Roger et al.
CLINICAL PHARMACOKINETICS (2017)
Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
Takayuki Katsube et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Clearance of ceftazidime-avibactam in an in vitro continuous venovenous hemodialysis model
Kristen L Bunnell et al.
Open Forum Infectious Diseases (2017)
Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials
Elizabeth L. Alexander et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy
Brandon Eilertson et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
Shuhei Matsumoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration
Eric Wenzler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy
Weerachai Chaijamorn et al.
BLOOD PURIFICATION (2017)
Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration
Bradley A. Boucher et al.
PHARMACOTHERAPY (2016)
Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid
Paddy K. C. Janssen et al.
THERAPEUTIC DRUG MONITORING (2016)
Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy
Susan J. Lewis et al.
BLOOD PURIFICATION (2015)
How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?
Janattul-Ain Jamal et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
Can we use an ex vivo continuous hemofiltration model to describe the adsorption and elimination of meropenem and piperacillin?
Janattul-Ain Jamal et al.
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS (2015)
Colistin Pharmacokinetics in Burn Patients during Continuous Venovenous Hemofiltration
Kevin S. Akers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy
Tyree H. Kiser et al.
CRITICAL CARE (2015)
A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics
Darren M. Roberts et al.
CRITICAL CARE (2015)
Trimethoprim and Sulfamethoxazole Transmembrane Clearance during Modeled Continuous Renal Replacement Therapy
Jacob M. Kesner et al.
BLOOD PURIFICATION (2014)
Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration
Jason A. Roberts et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy
Marjorie Beumier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives
Ashit Trivedi et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2013)
Principles of antibacterial dosing in continuous renal replacement therapy
Gordon Choi et al.
CRITICAL CARE MEDICINE (2009)
A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?
A. M. M. Y. Li et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis
Lena M. Maynor et al.
PHARMACOTHERAPY (2008)
Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury
A. Mary Vilay et al.
CRITICAL CARE (2008)
Adsorption of amikacin, a significant mechanism of elimination by hemofiltration
Qi Tian et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Drug dosing in continuous renal replacement therapy: general rules
Miet Schetz
CURRENT OPINION IN CRITICAL CARE (2007)
Improvement of outcomes after coronary artery bypass II: A randomized trial comparing intraoperative high versus customized mean arterial pressure
Mary E. Charlson et al.
JOURNAL OF CARDIAC SURGERY (2007)
Practice patterns in the management of acute renal failure in the critically ill patient: an international survey
Z Ricci et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Daptomycin clearance during modeled continuous renal replacement therapy
Mariann D. Churchwell et al.
BLOOD PURIFICATION (2006)
Cefepime and continuous renal replacement therapy (CRRT):: In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients
A Isla et al.
CLINICAL THERAPEUTICS (2005)
Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters
S Troyanov et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution
S Uchino et al.
INTENSIVE CARE MEDICINE (2002)
Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients
RS Malone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
